Portola Pharmaceuticals Inc (PTLA) Given Consensus Rating of “Buy” by Analysts

Shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) have received an average rating of “Buy” from the twelve brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and nine have given a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $71.31.

A number of analysts have weighed in on PTLA shares. Oppenheimer reissued a “buy” rating and set a $80.00 target price on shares of Portola Pharmaceuticals in a research report on Wednesday, September 6th. BidaskClub cut Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 19th. Goldman Sachs Group assumed coverage on Portola Pharmaceuticals in a report on Friday, December 1st. They set a “buy” rating and a $75.00 price target on the stock. Morgan Stanley restated an “overweight” rating and set a $81.00 price target (up from $75.00) on shares of Portola Pharmaceuticals in a report on Friday, October 6th. Finally, Credit Suisse Group upgraded Portola Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $70.00 price target on the stock in a report on Wednesday, August 23rd.

Several institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. lifted its holdings in shares of Portola Pharmaceuticals by 0.9% in the 2nd quarter. BlackRock Inc. now owns 4,071,966 shares of the biopharmaceutical company’s stock worth $228,721,000 after purchasing an additional 37,241 shares in the last quarter. State Street Corp lifted its holdings in shares of Portola Pharmaceuticals by 5.3% in the 2nd quarter. State Street Corp now owns 2,085,838 shares of the biopharmaceutical company’s stock worth $117,164,000 after purchasing an additional 105,207 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Portola Pharmaceuticals by 3.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 744,702 shares of the biopharmaceutical company’s stock worth $40,081,000 after purchasing an additional 26,544 shares in the last quarter. Kornitzer Capital Management Inc. KS lifted its holdings in shares of Portola Pharmaceuticals by 38.7% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 727,812 shares of the biopharmaceutical company’s stock worth $39,324,000 after purchasing an additional 202,925 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Portola Pharmaceuticals by 17.2% in the 2nd quarter. Goldman Sachs Group Inc. now owns 688,092 shares of the biopharmaceutical company’s stock worth $38,650,000 after purchasing an additional 101,046 shares in the last quarter. Institutional investors own 87.45% of the company’s stock.

Portola Pharmaceuticals (NASDAQ:PTLA) traded up $0.31 during trading hours on Friday, reaching $53.02. 713,244 shares of the company’s stock were exchanged, compared to its average volume of 967,150. The company has a debt-to-equity ratio of 0.24, a current ratio of 8.31 and a quick ratio of 8.31. Portola Pharmaceuticals has a twelve month low of $17.74 and a twelve month high of $67.10.

Portola Pharmaceuticals (NASDAQ:PTLA) last released its earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.08. The business had revenue of $3.83 million during the quarter, compared to the consensus estimate of $4.71 million. Portola Pharmaceuticals had a negative net margin of 938.19% and a negative return on equity of 110.46%. The company’s revenue for the quarter was down 58.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.64) EPS. sell-side analysts expect that Portola Pharmaceuticals will post -4.95 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Portola Pharmaceuticals Inc (PTLA) Given Consensus Rating of “Buy” by Analysts” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/08/portola-pharmaceuticals-inc-ptla-given-consensus-rating-of-buy-by-analysts.html.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Analyst Recommendations for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply